Life Sciences Archive » October, 2024

Life Sciences - October, 2024

284 articles

• Judge 'Duped' By BigLaw Attys Urged To Preserve Sanctions
• IP Forecast: Another Apple Watch Trial Kicks Off In California
• NY Court Urged To Reject 'Audacious' Shareholder Test Cases
• CVS Unit Exec's Ex-Partner Charged With Insider Trading
• Drug Cos. To Pay $49M For State-Led Generic Pricing Claims
• Masimo Sues Ex-CEO Over 'Unprecedented' $450M Demand
• Purdue Gets More Time For Deal, 'Substantial' Progress Made
• Flint Water Case Paused For 'Advanced' Settlement Talks
• Judge Upholds Sanctions Against Ex-Stimwave CEO
• How Judiciary Can Minimize AI Risks In Secondary Sources
• Newly Acquired Information Can Be Key In Drug Label Cases
• The 2024 Law360 Pulse Leaderboard
• Firms' Hiring Strategies Are Evolving In Fight For Top Spot
• Teva Fined €463M For Blocking Rival MS Drug Launch
• FDA Didn't Flub Approval In Orphan Drug Case, DC Court Says
• Alleged Kickback Plotters Can Waive Conflict Over Attorney
• Cigna Wants $16.1M, Florida Labs Seek $5.1M In Benefits Feud
• LA Times Owner Faces Investor Suit Over Drug Co.'s Woes
• After Exeltis Win, Judge Won't Allow Suits On Dropped Patents
• Publix Denied Early Win Over Opioid Coverage Defense
• 3rd Circ. Told Medicare Drug Price Talks Not Voluntary
• Biopharma Co. Can't Knock Ex-CFO's Bias Suit Out Of Court
• Ex-Takeda Exec. Gets Nearly 4 Years For Fake Invoice Scam
• Yale Researcher's Suit Over Loss Of 'Life's Work' Transferred
• Ohio PBM Case Will Wait For High Court Ruling
• DLA Piper's FDA Regulation Vice Chair Joins White & Case
• Nvidia Case's Potential Impact On Securities Class Actions
• How Attorneys Can Break Free From Career Enmeshment
• NY Judge Tosses $14B Decongestant MDL
• Y-mAbs Therapeutics Investors Get Final OK For $19.7M Deal
• Retired Fed. Circ. Judge Backs Invisalign In Monopoly Cases
• Patent Partner Moves From King & Spalding To Steptoe
• 4th Circ. Quizzes Drugmaker Challenging W.Va. Abortion Law
• Biopharma Co. Escapes Investor Suit Over Drug Approval Lies
• Medical Co. Gets No Coverage For Toxic Tort
• Investors Float $21M Deal To End Life Sciences SPAC Suit
• Beyond Abortion, 7 Ballot Questions Set To Shape Care
• Allergan, Mankind Settle IP Fight Over Lumigan Generic
• Purdue Creditors Can Sue Sacklers For $11.5B
• Pa. DA Says ATF's Pot Patients Ban Doesn't Fit With Bruen
• Senate Panel Targets 'Clever' Pharma Pricing
• Key Healthcare Issues That Hinge On The Election Outcome
• Patent Lessons From 4 Federal Circuit Reversals In September
• Circuit Judge Rips Atty's 'Unearned Windfall' In Liability Case
• Crescent Inks Oncology Merger With $200M In Private Funding
• PE-Owned Implant Maker Plagued By Lawsuits Hits Ch. 11
• Lawyers With Disabilities Are Seeking Equity, Not Pity
• Masimo Sues Founder Over Alleged 'Empty Voting' Scheme
• Sterigenics Says Residents Can't Tie Harms To Ethylene Oxide
• Flint Bellwether Delayed On Eve Of Trial, Again
• Judge Leaves Patent Case After Fed. Circ. Undoes Ruling
• Judge Tosses Hearing-Loss MDL Bellwether With Voided Law
• Moderna Brass Hit With Investor Suit Over RSV Shot Claims
• Pfizer Urges Court Not To Ax Delay Defense In Vax IP Fight
• Mass. Court's Wiretap Ruling May Be Bad Omen For Plaintiffs
• AbbVie Paying $1.4B For Alzheimer's-Focused Biotech
• Medical Laser Co. Seeks Multiplier For Rival's 'Deceitful' Raid
• Judicial Committee Best Venue For Litigation Funding Rules
• Crown Settles Customer Dispute To Close $924M Revance Buy
• Inari Wins Bid To Kill Plant Gene Patent At PTAB
• Vidal Warned Of 'Heightened' Burden, 'Loophole' In Seed Fight
• NJ Ethics Board Faces Contempt Bid In Retaliation Fight
• Feds Seek 6½ Years For Ex-Takeda Worker Over Invoice Fraud
• High Court Bar's Future: Mitchell Law's Jonathan F. Mitchell
• Pharmacy Must Pay $39.2M In Conn. Kickback Case
• The Strategic Advantages Of Appointing A Law Firm CEO
• UK Litigation Roundup: Here's What You Missed In London
• FTC Official Doubts Election Will Deter Antitrust 'New Era'
• Del. Co. Tells 3rd Circ. €4.2M Award Was Properly Denied
• IP Forecast: Inhibrx Co-Founder Faces Biotech Secrets Trial
• 7th Circ. Doubts Satanic Temple Can Wage Abortion Fight
• Sen. Presses US Trade Rep To Take Up Fentanyl Probe
• 'Will Of The People' Upheld With Ohio Abortion Ban Quashed
• PBMs Want Separate FTC Hearings Over Insulin Prices
• Bayer Hit With False-Ad Suit Over Malic Acid In Vitamins
• How 2 Proposed Bills Could Transform Patent Law
• ITC Bans Foreign Counterfeit Tourniquets
• Mass. Justices Reject Meta, Google 'Wiretap' Claims
• Beekeeping Makes Me A Better Lawyer
• Late Smoker's Spouse Can Argue Survivor's Benefits At Retrial
• NM Pot Cos. Say Border Agents Wrongfully Seized Product
• SoClean Says Philips Can't Stand In For Damaged CPAP Users
• Budding Lessons From Landmark Plant Seed Patent Battle
• Merck Bets More Than $1B On Yale Cancer Treatment Spinout
• Former Axinn Hatch Waxman Attys Team Up At Polsinelli
• Roche CEO Says Novo-Catalent Deal Should Be Blocked
• Suit Over Wash. Ban On 'DIY' Rape Evidence Kits Nixed
• Pharma Co. Verrica Faces Derivative Suit Over FDA Inspection
• Biotech Cos. Keep Dancing Despite Purple Book Disclosures
• IQVIA, Veeva Blast Summary Judgment Bids In Secrets Suit
• Ark. Supreme Court Voids Nov. Effort To Expand Medical Pot
• Patent Office Finds Public Engagement Leader
• The Key To Solving High Drug Costs Is Understanding Causes
• Judge Skeptical Amgen Can't Sue Over Colo. Drug Price Caps
• LA-Based Wound Group Hits Ch. 11 After Medicare Pay Pause
• NJ Justices Create Mass Tort Track For Bard Catheter Suits
• Legal Institutions Must Warn Against Phony Election Suits
• Bring Back Patent Models To Shut Down The Patent Trolls
• The 2024 Prestige Leaders
• How Law Firms Get And Keep Elite Status
• In-House Counsel For Veeva, SingleStore Joins Stoel Rives
• Eli Lilly Slams 'Dangerous' Knock-Off Weight Loss Drugs
• Apple Tells Del. Jury It Wants Smartwatch Infringing To Stop
• FDA Tells Court Menthol Cigarette Ban Is Still Under Review
• PBMs Keep Door Open To Constitutional Riposte Against FTC
• GOP Pols Want Probe Into FDA Laboratory Safety
• Novartis Loses Challenge To Medicare Drug Price Talks
• Strategies To Avoid Patent Issues In AI Drug Discovery
• Goodwin Steers Biotech Firm Septerna's Plans For $175M IPO
• McGuireWoods Adds Healthcare Atty From Cooley In NY
• How Cos. Can Build A Strong In-House Pro Bono Program
• Bristol-Myers Win Offers Lessons For Debt Security Holders
• Catalent CEO Defends Novo Deal, Will Stay On After Buyout
• Law360 MVP Awards Go To Top Attys From 74 Firms
• What Attorneys Expect From Harris And Trump On Patents
• Chancery Keeps Better Therapeutics SPAC Suit Alive
• Fed. Circ. Won't Question Reviving Vascepa Skinny Label Row
• Cigna Says Florida Labs Owe $16M After 'Cheating' For Benefits
• Teva Signs Deal With Indirect Buyers In Effexor Antitrust Suit
• Biotech Co. Wins Injunction Against Ex-Worker In Secrets Suit
• Home Canning Makes Me A Better Lawyer
• Navigating The Bankruptcy Terrain After Purdue Pharma
• 5 Considerations For Obviousness-Type Double Patenting
• Taxation With Representation: Baker, Simpson, Ropes
• Philly Atty Suspended After Guilty Plea In Pill Mill Scheme
• FTC Faces More Pressure To Block $16.5B Novo-Catalent Deal
• Pfizer Escapes 401(k) Fee Suit Due To Poor Comparisons
• E-Cig Regs Are Congress' Job, Not FDA's, GOP Pols Tell Justices
• 'More Honesty' Needed In Philips IP Row, Judge Says
• Justices Urged To Fix 'Novel Misreading' Of IP Safe Harbor
• Northwestern Hits Moderna With Patent Suit Over COVID Vax
• Amgen Faces Derivative Suit In Del. Over Tax Disclosures
• Oregon Appeals Court Says E-Cig Rules Violate Free Speech
• $20B Verizon-Frontier Deal Faces Scrutiny, And Other Rumors
• Ex-Genzyme Exec Says Anxiety Disclosure Led To Firing
• Moderna Wants Fees For 'Frivolous' COVID-19 Vax Suit
• Patent Lessons From 7 Federal Circuit Reversals In August
• Use The Right Kind Of Feedback To Help Gen Z Attorneys
• Philips Says $12M Sanction Needed For Evidence Destruction
• Apple Heart Rate Monitor Patent Survives PTAB
• Direct Buyers Get Final OK For $44M Drug Price-Fixing Deal
• Pharma Co. Contractor Settles SEC Insider Trading Claim
• Ex-Pharma Co. Employee Traded On GSK Deal Info, SEC Says
• Congress Can And Must Enact A Supreme Court Ethics Code
• SEC To Settle Claims CBD Exec Took $13M From Hospital
• Caremark, Optum Say FTC Insulin Case Gets PBMs All Wrong
• Houston Pharma Exec Found Guilty In $160M Health Fraud
• AAM, Alvogen Back Sun Pharma In Double Patenting Row
• M&A Pros Cautious About Expected Private Equity Surge
• The Pop Culture Docket: Justice Lebovits On Gilbert And Sullivan
• Horizon Lodges 4-Fold Attack On Tepezza MDL Bellwethers
• Judge Backs Exelixis Cancer Drug Patent Claims
• Motley Rice May Avoid DQ In Boston Opioid Case, Judge Hints
• GSK Says Moderna's COVID, RSV Vax Infringe MRNA Patents
• New HHS Research Misconduct Rules Bring Seismic Changes
• Justices Mull RICO's Scope In Trucker's CBD Case
• Walmart, Execs Settle Chancery Opioid Suit For $123M
• Novartis To Appeal Ruling In Entresto Generic Drug Fight
• Feds Cut Whistleblowers Out Of Kickback Deal, Court Told
• Skadden Picks Up Arbitration Co-Head From Sidley In Asia
• Law Firms Diverge As Anti-ESG Pushback Continues
• The 2024 Law360 Pulse Social Impact Leaders
• Ill. Home Health Kickbacks Ruling Intact After Justices Pass
• Baker McKenzie Leads Lundbeck's $2.6B Deal For US Pharma
• Pharmacist Gets Up To 15 Years In Mich. For Fatal Outbreak
• High Court's TCPA Grant Set To Broaden Loper Bright's Blow
• Apotex Accused Of Infringing Novo Nordisk Diabetes Drug
• Up Next At High Court: CBD Injuries & The Clean Water Act
• Apple Watch Patents Dodge Ax As Masimo Jury Trial Nears
• Medytox Loses ITC Fight Over Antiwrinkle Trade Secrets Use
• Texan Who Sued Ex's Colleagues Over Abortion Drops Suit
• J&J Should Pay $30M For Developer's Cancer, Conn. Jury Told
• Justices Will Evaluate RICO Scope In Trucker's CBD Case
• Swiss Officials Clear Novartis IP Suits As 'Common Practice'
• 9th Circ. Backs Planned Parenthood's $14M Atty Fee Win
• 'Bloodsport' Poaching Case To Mediate After Disputed Verdict
• UK Litigation Roundup: Here's What You Missed In London
• State Of The States' AI Legal Ethics Landscape
• Animal Medication Co. Sued Over Dog Arthritis Treatment Risks
• Federal Policy Can't Kill Psilocybin Access Suit, Court Told
• How Biden Admin Has Used Antitrust Tools, And What's Next
• Biotech Co. Gritstone Hits Ch. 11 With Over $100M Debt
• Target Made Inflated Claims About Gas Pills, Shoppers Allege
• Teva To Pay $450M To Settle Kickback Cases
• Defining All-Risk: Despite $30M Loss, Loose Bolt Not 'Damage'
• Sen. Warren, Novo At Odds On Merits Of $16.5B Deal
• Pfizer Threatened To Sue Former Execs, Starboard Says
• The Shifting Role Of Patent Attorneys In The Age Of AI
• Hyundai Plans IPO For Indian Biz, Plus More Rumors
• 8 Childhood Lessons That Can Help You Be A Better Attorney
• CVS, United Health Seek Removal Of FTC's Khan In PBM Case
• Philips Preserves Lanham Act Counterclaim In CPAP Cleaner MDL
• Companies' Kratom Supplements Are Addictive, Class Says
• DLA Piper Adds Former Faegre Drinker Litigator In Philly
• GSK Settles Nearly All State Zantac Cases For Up To $2.2B
• Lead Test Maker Vows Compliance As $42M Deal Approved
• Medical Device Service Co. Hits Ch. 11 After Fight With Rival
• This Election, We Need To Talk About Court Process
• Apple Loses Bid For Jury Trial In Masimo Trade Secrets Fight
• Illumina Wants Unresponsive Plaintiff To Pay $200K, Atty Fees
• Ropes & Gray Attys Chided For Wielding Excessive Footnotes
• Jackson, Kagan Target Loper Bright In Ghost Gun Case
• Fed. Circ. Mulls Trade Dress Fight Over Pink Hip Devices
• 2nd Circ. Won't Revive 1-800 Contacts, Warby Parker Row
• CooperSurgical Fails To Escape Embryo Solution Recall Suits
• Elanco Misled Investors About Dog Medicine Safety, Suit Says
• 3rd Circ. Directs Court To Explain If Natera Ads 'Literally False'
• 3rd Circ. Preview: Constitutional Rights Fears Top October
• J&J Greenwashes '100% Plant-Based' Wipes, Suit Says
• A Look At The PTAB's Assessment Of Prior Art Exceptions
• Doctor Wants New Trial In $16.4M Suit Over Patient's Suicide
• Playing Diplomacy Makes Us Better Lawyers
• College Admins Beat Ex-Prof's Suit Over Race-Based Study
• 9th Circ. Asked To Take Another Look At 'Patent Misuse' Case
• AbbVie's Top Brass Escape Suit Over Rinvoq Claims, For Now
• Boehringer Defends Zantac As Cancer Jury Trial Kicks Off
• ITC Judge Pushes For Import Ban In Liver Drug Secrets Row
• Fed. Circ. Questions If Safer OxyContin Profits Came From IP
• Merck Immune For 'Inflated' Vax Claims To FDA, 3rd Circ. Says
• Biotech, Medical Device Firms Prep Three IPOs Totaling $376M
• Mich. Supreme Court Snapshot: Insulin Prices, Disney Audit
• Mylan, Novo Nordisk Settle Ozempic Patent Dispute
• 5 Decisions To Know By Outgoing Mass. Chief Judge
• Trio Of 1st Circ. Criminal Cases Turned Away By Top Court
• How Patent Litigation Is Changing Amid Decline In Filings
• Justices Won't Hear Kickback Statute 'Willfulness' Case
• High Court Rejects Pleas To Hear 7 Patent Cases
• High Court Won't Look At Alabama Frozen Embryo Decision
• Justices Won't Hear Shkreli's Bid To Undo $64M Disgorgement
• Top 5 Supreme Court Cases To Watch This Fall
• NJ, Ethics Board Must Hand Over Docs In Retaliation Fight
• DOJ Charges Execs, Sales Reps Over Texas 'Pill Mills' Sales
• Regeneron Can't Ax Willful Infringement In COVID Patent Case
• Healthcare Co. Inks Deal In DOL Equal Pay Investigation
• There May Not Be Life On Mars, But There Could Be IP
• Mental Health First Aid: A Brief Primer For Attorneys
• UK Litigation Roundup: Here's What You Missed In London
• High Court Takes Up E-Cig 'Forum Shopping' Appeal
• High Court Will Hear TCPA Case Over Online Junk Faxes
• Gilead Makes Generic HIV Drug Plan, Advocates Urge Expansion
• Boston Pharma Co. Drops Another Moderna Patent Suit
• Del. Vice Chancellor Slams Fee Terms In Advancement Case
• Trulieve Sues Fla. Republican Party Over Anti-Weed Ads
• FibroGen Suit Alleging Disclosure Failures Tossed In Del.
• 12 Lawyers Who Are The Future Of The Supreme Court Bar
• Stanford Profs Deny Roche's Trade Secret Theft Accusations
• FTC's Report Criticizing Drug Middlemen Is Flawed
• Texas Takes Aim At Insulin Manufacturers For Price-Gouging
• Flint Water Judge Wishes Public Knew Case Complexity
• NJ Contractors Accused Of $10M Fraud In Lead Removal Work
• Cos. Want Federal Rule On Litigation Funding Disclosure
• Ex-US House Energy Committee Atty Joins Foley In DC
• CVS Pushed To Unwind Aetna Megadeal, And Other Rumors
• Collecting Art Makes Me A Better Lawyer
• Bard Agrees To Individualized Deals In Hernia Mesh Litigation
• Chancery To Mull Receiver In Drug Co. Consulting Bill Row
• Pfizer Didn't Warn Of Tumor Risks In Depo-Provera, Suit Says
• Avadel Tells Fed. Circ. It Should Be Free To Test Sleep Drug
• Amarin Says Sky Isn't About To Fall In Skinny Labels Fight
• Doctor Cops To Dealing Ketamine That Killed Matthew Perry
• Dental Laser Maker Biolase Hits Ch. 11 With $33M In Debt
• Del. Dispatch: Cautionary Tales Of 2 Earnout Effort Breaches
• Supplement Co. Hits Back At TM Suit, Alleges Fake Reviews
• Takeaways From Novo Nordisk's Fight For Market Exclusivity
• GNC Wins $45M In Awards Against Asian Franchisees
• Fla. Atty Disbarred For Abandoning Pharma Biz Before USPTO
• ExecuPharm Agrees To Pay Ransomware Victims $10K Each
• Using Primacy And Recency Effects In Opening Statements
• Secret Service Failures Offer Lessons For Private Sector GCs
• Bill Is Key To Protecting US Economy From Patent Piracy
• Teva Sales Workers Get $2.7M Unpaid OT Deal Approved
• From AI To Enviro: The Top Biz Bills Calif. Gov. Inked Into Law
• 9th Circ. Cites 'Sunscreen' Song In Reviving Banana Boat Suit
• Judge Backs Louisiana 340B Law In Loss For Pharma Lobby
• Activists Sue Ark. Officials Over Medical Pot Ballot Measure
• Ex-CBD Exec Must Face SEC Fraud Suit Over $13M Deal
• DOJ Says It Is Constitutional To Disarm Pot Patients
• Amgen Must Face Suit It Misled Investors On $10.7B Tax Bill
• Biotech Investors Reach $32.5M Deal Over Failed COVID Test
• Defending AI, Machine Learning Patents In Life Sciences
• WilmerHale Lands Latham Life Sciences Ace In Bay Area
• Litigation Inspiration: Honoring Your Learned Profession
• From Concept To Capital: 5 Stages Of Evolving IP Needs
• Nostrum Labs Hits Ch. 11 A Year After Medicaid Settlement